Please login to the form below

Not currently logged in
Email:
Password:

Pulmicort Respules

This page shows the latest Pulmicort Respules news and features for those working in and with pharma, biotech and healthcare.

AZ gets injunction to protect Pulmicort Respules

AZ gets injunction to protect Pulmicort Respules

AZ gets injunction to protect Pulmicort Respules. Actavis blocked from selling generic five days after AZ’ s asthma launch. ... Actavis has been blocked from selling its generic version of AstraZeneca's asthma drug Pulmicort Respules five just days

Latest news

  • AZ loses Pulmicort Respules protection in US AZ loses Pulmicort Respules protection in US

    AZ loses Pulmicort Respules protection in US. Court also denied AZ’ s request for a permanent injunction. ... AstraZeneca (AZ) was dealt a major blow by a US court after a key patent protecting its Pulmicort Respules product was invalidated.

  • AstraZeneca hit by US Pulmicort patent ruling AstraZeneca hit by US Pulmicort patent ruling

    AstraZeneca (AZ) suffered another setback yesterday when a US federal court ruled that a patent for its inhaled steroid drug Pulmicort Respules was invalid. ... If upheld, the decision will cut more than five years from the exclusivity period for

  • AZ discontinues asthma medicine

    AZ discontinues asthma medicine. AstraZeneca is to discontinue production of an inhaled version of its asthma medication Pulmicort due to 'manufacturing issues'. ... Other unaffected products include AZ's Pulmicort Turbuhaler, Pulmicort Respules and

  • Generics and legal costs affect AZ profits

    The core products affected by generic competition are Toprol-XL (metoprolol succinate) – a high blood pressure medication, asthma treatment Pulmicort Respules (budesonide inhalation suspension) and the company's breast cancer drug

  • Positive Q1 figures for AstraZeneca

    Sales of asthma drug, Symbicort increased in all markets globally, while sales of Pulmicort were down 37 per cent in the US. ... The impact on sales of Pulmicort Respules that can be attributed to Teva's generic budesonide inhalation suspension product

More from news
Approximately 3 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Adelphi Research UK

Adelphi Research UK is a healthcare insight partner. We uniquely blend robust market research with a consultancy approach, to guide...

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics